Insider Sale: PRESIDENT AND CEO of $MRAM Sells 12,950 Shares
Insider Trading Activity: Sanjeev Aggarwal, CEO of $MRAM, sold 12,950 shares for approximately $61,771, representing about 2.0% of his holdings, while insiders have made 11 sales and no purchases in the past six months.
Institutional Investor Movements: In the last quarter, 31 institutional investors increased their positions in $MRAM stock, while 27 reduced theirs, indicating mixed sentiment among large shareholders.
Get Free Real-Time Notifications for Any Stock
Analyst Views on MRAM
No data
About MRAM
About the author
High Roller Technologies Inc Closes Direct Offering, Raises $25 Million
- Successful Financing: High Roller Technologies Inc announced the completion of a registered direct offering of 1.89 million common shares at $13.21 per share, raising approximately $25 million in gross proceeds, significantly enhancing the company's liquidity to support future business expansion.
- Stock Surge: Following this announcement, High Roller’s shares jumped 29.6% to $10.21 in pre-market trading, reflecting strong market confidence in the company's growth potential and likely attracting more investor interest.
- Positive Market Reaction: The successful financing not only improves High Roller’s capital structure but also positions the company to gain a stronger competitive edge in the fiercely competitive online gaming market, aiding in further market share expansion.
- Strategic Growth Outlook: With this financing, High Roller Technologies can accelerate its strategic plans, including technological innovation and market expansion, which is expected to bring long-term growth opportunities and enhance shareholder value.
Zscaler Expected to Surge Over 9%? Check Out 10 Leading Analyst Predictions for Monday
Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including Piper Sandler lowering SITE Centers' target from $12 to $10 while maintaining an Overweight rating.
Upgrades and Downgrades: Notable upgrades include Leerink Partners raising Eli Lilly's target from $886 to $1,104 and upgrading the stock from Market Perform to Outperform, while Stifel downgraded Trex Company from Buy to Hold, cutting its target from $61 to $35.
Price Target Increases: Companies like Genmab and Everspin Technologies saw their price targets increased by HC Wainwright & Co. and Needham, respectively, with Genmab's target rising from $40 to $41 and Everspin's from $8 to $10.5.
Significant Cuts: Rothschild & Co. significantly reduced HubSpot's price target from $610 to $450, downgrading it from Buy to Neutral, while Morgan Stanley cut Norwegian Cruise Line's target from $27 to $25, maintaining an Equal-Weight rating.
